NovaBay Pharmaceuticals, Inc. (NBY) |
| 1.53 -0.02 (-1.29%) 02-26 16:00 |
| Open: | 1.5 |
| High: | 1.675 |
| Low: | 1.42 |
| Volume: | 387,515 |
| Market Cap: | 40(M) |
| PE Ratio: | 0.06 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 5.99 |
| Resistance 1: | 3.87 |
| Pivot price: | 0.91 |
| Support 1: | 0.43 |
| Support 2: | 0.36 |
| 52w High: | 99.75 |
| 52w Low: | 1.42 |
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Wed, 25 Feb 2026
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Price Passes Below 50-Day Moving Average - Here's What Happened - MarketBeat
Fri, 20 Feb 2026
NovaBay Pharmaceuticals enacts 1-for-5 reverse stock split - Investing.com
Fri, 20 Feb 2026
NovaBay Pharma Implements Reverse Stock Split of Shares - TipRanks
Thu, 12 Feb 2026
NovaBay Pharmaceuticals Announces 1-for-5 Reverse Stock Split - TradingView
Wed, 28 Jan 2026
Auditor change as NovaBay (NBY) seeks approval to dissolve - Stock Titan
Tue, 20 Jan 2026
NovaBay Pharmaceuticals (NBY) Announces $100M Stock Sale Agreement with Virtu Americas - Intellectia AI
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |